Isoray (NYSE:ISR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Isoray (NYSE:ISRGet Rating) in a research note released on Monday. The brokerage issued a sell rating on the stock.

NYSE ISR opened at $0.34 on Monday. The stock has a market capitalization of $48.44 million, a PE ratio of -7.04 and a beta of 0.98. Isoray has a 52-week low of $0.31 and a 52-week high of $1.09. The business’s 50-day moving average price is $0.35.

Isoray Company Profile (Get Rating)

IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.

Featured Stories

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.